ClinicalTrials.gg
RecruitingNCT07569549BASTIONUpdated Oct 9, 2026

Surgery for Thumb Base Osteoarthritis: Joint Replacement vs. Trapeziectomy

An interventional study of Implantation of trapeziometacarpal prosthesis and Trapeziectomy with Capsuloplasty in Thumb Osteoarthritis, Thumb Carpometacarpal Joint Osteoarthritis and Carpometacarpal (CMC) Joint Arthritis, sponsored by Uppsala University. Recruiting at 1 site in Sweden. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Uppsala University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 9, 2026Start date movedEligibility revised+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Study summary

The goal of this clinical trial is to learn if the surgical method with total joint arthroplasty, (TOUCH joint prosthesis), is as good as or better than the traditional surgical method, trapezectomy, to treat thumb base joint osteoarthritis.

The main questions it aims to answer are:

Does surgery with total joint arthroplasty provide better power grip and pinch grip strength compared to traditional surgery?

What is the long-term risk of complications for both methods?

Which method is more cost-effective for the healthcare system?

Researchers will compare total joint arthroplasty (TOUCH) to trapezectomy (a procedure where a bone in the thumb base is removed) to see which method provides the best results for the patient.

Participants will:

Be randomized to undergo either an operation with total joint arthroplasty or a trapezectomy.

Undergo an initial evaluation and a health economic cost analysis after one year.

Attend follow-up checkups at 2, 5, and 10 years post-surgery to evaluate long-term function and the durability of the prosthesis.

Read the detailed description

Background and Rationale:

Basal joint arthritis of the thumb (trapeziometacarpal osteoarthritis) is a common condition causing pain and reduced hand function. While trapeziectomy with ligament reconstruction/capsuloplasty has long been a gold standard, total joint arthroplasty, such as the TOUCH prosthesis, has gained popularity. However, there is a lack of high-quality prospective randomized controlled trials (RCTs) comparing these methods regarding long-term functional outcomes, complication rates, and cost-effectiveness. This study aims to compare the clinical and health-economic outcomes of total joint arthroplasty with TOUCH prosthesis versus trapeziectomy with capsuloplasty.

Study Design and Randomization:

This is a prospective, randomized controlled trial. Following informed consent obtained by the attending surgeon, participants are randomized to either:

  1. Total joint arthroplasty using the TOUCH prosthesis.
  2. Trapeziectomy with capsuloplasty. Randomization is performed in close proximity to the day of surgery. Due to the nature of the interventions, participants are informed of the surgical method postoperatively.

Procedures and Follow-up

  • Surgical Intervention: Both procedures are performed according to standardized institutional protocols.
  • Postoperative Care (Trapeziectomy): The thumb is immobilized in a cast for 3 weeks, followed by a standardized rehabilitation program led by occupational and physical therapists.
  • Postoperative Care (total joint arthroplasty): A stable soft dressing is applied for 3 weeks, followed by the same rehabilitation protocol.
  • Follow-up Schedule: Participants are evaluated at 3 weeks, 6 weeks, 12 weeks, 12 months, 24 months, 5 years, and 10 years postoperatively.
  • Imaging: Radiographic evaluations are performed for the prosthesis group at 6 weeks, 12 months, 24 months, 5 years, and 10 years to monitor for prosthesis loosening or "z-deformity" (MCP joint hyperextension) compared to the trapeziectomy group.

Data Management and Quality Assurance:

Data is collected and managed using REDCap (Research Electronic Data Capture) to ensure data integrity and validation. Physical informed consent forms are stored securely at the Department of Hand Surgery. Source data verification is performed by comparing registry data against electronic medical records and paper-based Case Report Forms (CRFs).

Sample Size and Power Calculation:

The primary outcome is Jamar grip strength at 12 months. Based on a Minimal Clinically Important Difference (MCID) of 6.5 kg and a standard deviation (SD) of 8.5 kg (derived from existing literature and pilot data), a power calculation (90% power, alpha 0.05, two-sided t-test) determined a requirement of 37 patients per group. To account for a 10% dropout rate, the total cohort size is set at 84 patients (42 per arm).

Health Economic Analysis:

A comprehensive health economic evaluation will be conducted to compare the total costs of both methods. This analysis includes:

  • Direct Costs: Implant costs, anesthesia, surgical time, and healthcare utilization (number of visits).
  • Indirect Costs: Duration of sick leave and time to return to work.
  • Secondary Metrics: Analgesic consumption (paracetamol and opioids), patient-reported quality of life (EQ-5D), and "pain-free days" based on NRS (Numerical Rating Scale) assessments.

The objective is to determine if the higher initial cost of the TOUCH prosthesis is offset by faster recovery, reduced sick leave, and improved long-term productivity.

02

Conditions studied

  • Thumb Osteoarthritis
  • Thumb Carpometacarpal Joint Osteoarthritis
  • Carpometacarpal (CMC) Joint Arthritis
  • Basal Thumb Osteoartrithis

Keywords

  • Thumb base arthroplasty
  • CMC joint
  • prosthesis
  • hand surgery
  • First Carpometacarpal Joint
  • Trapeziometacarpal Joint
  • Rhizarthrosis
  • Thumb Osteoarthritis
  • Dual Mobility Prosthesis
  • Total Joint Replacement
  • Total Joint Arthroplasty
  • Ligament Reconstruction
  • Surgical Reconstruction
  • Randomized Controlled Trial (RCT)
  • Prospective Studies
  • Comparative Study
  • Prospective Study
  • Cost-Effectiveness Analysis
  • Cost-Benefit Analysis
  • Health Economics
  • Patient Reported Outcome Measures (PROMs)
  • Quality of Life (QoL)
  • Health-Related Quality of Life (HRQoL)
  • Return to Work
  • Grip Strength
  • Pinch Strength
  • QuickDASH
  • EQ-5D
  • Michigan Hand Outcomes Questionnaire (MHQ
  • Trapeziectomy
03

In context

Lead sponsor

Uppsala University is the lead sponsor of 390 studies on the registry; 86 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 9, 2026. See what changed

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 40-80 years at inclusion
  • CMC-joint osteoarthritis grade 1-3 (Eaton-Littler classification)
  • Rest pain or pain reducing hand function with indication for surgery
  • Insufficient relief from non-operative treatment for ≥3 months (orthosis, OTC analgesics, cortisone injection)
  • Eligible for both prosthesis and trapezectomy per including surgeon
  • Non-smoker or complete smoking cessation ≥6 weeks prior to surgery

Exclusion criteria

Exclusion Criteria:

  • Previous surgery to thumb base or STT-joint
  • Ongoing general chronic pain condition or other pain in the same hand predominant over the thumb base pain.
  • Dementia or cognitive impairment
  • Trapezium height \<7 mm on plain radiograph
  • Active smoker
  • Osteoarthritis grade 4 (Eaton-Littler)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    Arm 1 -Dual Mobility Prosthesis (TOUCH)

    TOUCH Total Joint Arthroplasty (n=42). Implantation of TOUCH trapeziometacarpal prosthesis (Kerimedical). Soft bandage for 3 weeks postoperatively, followed by rehabilitation per national guidelines.

    Device: Implantation of trapeziometacarpal prosthesis

  • Active comparator
    Arm 2 - Trapeziectomy and Capsular Reconstruction

    Trapezectomy with capsuloplasty (n=42). Excision of trapezium with dorsal capsule flap capsuloplasty. Cast immobilization for 3 weeks postoperatively, followed by rehabilitation per national guidelines.

    Procedure: Trapeziectomy with Capsuloplasty

Interventions

  • DeviceImplantation of trapeziometacarpal prosthesis

    Surgical implantation of the TOUCH trapeziometacarpal total joint prosthesis (Kerimedical). The prosthesis consists of an uncemented stainless steel stem inserted into the first metacarpal and a dual cup mobility system with a polyethylene ball articulating against a metal cup fixed in the trapezium. The stem is available in straight or 15-degree angled neck configurations. Postoperative management consists of a stable soft dressing for 3 weeks to allow early controlled mobilization, followed by a standardized hand therapy rehabilitation protocol.

    Also known as: TOUCH Dual-Mobility Prosthesis

  • ProcedureTrapeziectomy with Capsuloplasty

    Surgical excision of the trapezium bone (trapeziectomy) followed by capsuloplasty using a distally based dorsal capsular flap, without tendon interposition. The capsular flap is sutured to stabilize the base of the first metacarpal. No implant or tendon graft is used. Postoperatively, a cast immobilizing the thumb in functional position is applied for 3 weeks, followed by a standardized hand therapy rehabilitation protocol.

06

What researchers measure

Primary outcomes

  1. Hand grip strength

    Hand grip strength (JAMAR dynamometer) at 12 months post operatively

    Time frame: Measured at 12 months postoperatively

Secondary outcomes

  1. Key-pinch grip strength

    Key-pinch strength measured by pinch-gauge in kilograms

    Time frame: Measured at 6 weeks, 12 weeks, 12 months, 2 years, 5 years and 10 years postoperatively

  2. Pinch grip strength

    3-finger pinch strength measured by pinch gauge in kilograms

    Time frame: Measured at 6 weeks, 12 weeks, 12 months, 2 years, 5 years and 10 years postoperatively

  3. Postoperative Pain Intensity on a Numeric Rating Scale (NRS)

    Pain measured with the Numerical Rating Scale (NRS) at rest and load, where 0 is "no pain" and 10 is "worst imaginable pain"

    Time frame: Measured at 6 weeks, 12 weeks, 12 months, 2 years, 5 years and 10 years postoperatively

  4. Range of movement

    Range of movement of thumb measured by physiotherapist. Extension, flexion, volar abduction, radial abduction. In degrees.

    Time frame: Measured at 6 weeks, 12 weeks, 12 months, 2 years, 5 years and 10 years postoperatively

  5. Metacarpophalangeal (MCP)-joint hyperextension

    Radiographic MCP-joint hyperextension (Z-deformity)

    Time frame: Measured at 6 weeks, 12 weeks, 12 months, 2 years, 5 years and 10 years postoperatively

  6. Complications

    Complications, such as trigger thumb, de Quervain's, reoperation, and infection, reported within 12 months of surgery.

    Time frame: Measured at 6 weeks, 12 weeks, 12 months, 2 years, 5 years and 10 years postoperatively

  7. Use of analgesics

    Total usage of analgesic during the post operative period.

    Time frame: Measured at 6 weeks, 12 weeks, 12 months, 2 years, 5 years and 10 years postoperatively

  8. Duration of sick leave

    Total duration of sick leave.

    Time frame: Measured at 6 weeks, 12 weeks, 12 months, 2 years, 5 years and 10 years postoperatively

  9. Patient-reported outcomes EQ-5D

    Patient-reported outcome of the hand surgery using validated questionnaire EQ-5D

    Time frame: Measured at 6 weeks, 12 weeks, 12 months, 2 years, 5 years and 10 years postoperatively

  10. Patient-reported outcomes PRWHE

    Patient-reported outcome of the hand surgery using validated questionnaire PRWHE

    Time frame: Measured at 6 weeks, 12 weeks, 12 months, 2 years, 5 years and 10 years postoperatively

07

Study locations

1 of 1 sites recruiting
  • Department of Handsurgery, Uppsala University Hospital
    Uppsala, Sweden
    Recruiting
    • Elias Gardell, MD, attending hand surgeon · Contactelias.gardell@uu.se · +46(0) 186171544
    • Sara Edsfeldt, MD, PhD, senior attending · Contactsara.edsfeldt@uu.se · +46 (0) 186119031
    • Sara Edsfeldt, MD, PhD, senior attending · Principal investigator
08

References and documents

Publications

  • Werle S, Goldhahn J, Drerup S, Simmen BR, Sprott H, Herren DB. Age- and gender-specific normative data of grip and pinch strength in a healthy adult Swiss population. J Hand Surg Eur Vol. 2009 Feb;34(1):76-84. doi: 10.1177/1753193408096763. Epub 2009 Jan 7. PubMed 19129352 ↗
  • Kim JK, Park MG, Shin SJ. What is the minimum clinically important difference in grip strength? Clin Orthop Relat Res. 2014 Aug;472(8):2536-41. doi: 10.1007/s11999-014-3666-y. Epub 2014 May 10. PubMed 24817380 ↗
  • Lang CE, Edwards DF, Birkenmeier RL, Dromerick AW. Estimating minimal clinically important differences of upper-extremity measures early after stroke. Arch Phys Med Rehabil. 2008 Sep;89(9):1693-700. doi: 10.1016/j.apmr.2008.02.022. PubMed 18760153 ↗
  • Kierkegaard M, Petitclerc E, Hebert LJ, Mathieu J, Gagnon C. Responsiveness of performance-based outcome measures for mobility, balance, muscle strength and manual dexterity in adults with myotonic dystrophy type 1. J Rehabil Med. 2018 Feb 28;50(3):269-277. doi: 10.2340/16501977-2304. PubMed 29260836 ↗
  • Draak TH, Pruppers MH, van Nes SI, Vanhoutte EK, Bakkers M, Gorson KC, Van der Pol WL, Lewis RA, Notermans NC, Nobile-Orazio E, Leger JM, Van den Bergh PY, Lauria G, Bril V, Katzberg H, Lunn MP, Pouget J, van der Kooi AJ, van den Berg LH, van Doorn PA, Cornblath DR, Hahn AF, Faber CG, Merkies IS; PeriNomS study group. Grip strength comparison in immune-mediated neuropathies: Vigorimeter vs. Jamar. J Peripher Nerv Syst. 2015 Sep;20(3):269-76. doi: 10.1111/jns.12126. PubMed 26115516 ↗
  • Bohannon RW. Minimal clinically important difference for grip strength: a systematic review. J Phys Ther Sci. 2019 Jan;31(1):75-78. doi: 10.1589/jpts.31.75. Epub 2019 Jan 10. PubMed 30774209 ↗
  • Herren DB, Marks M, Neumeister S, Schindele S. Low complication rate and high implant survival at 2 years after Touch(R) trapeziometacarpal joint arthroplasty. J Hand Surg Eur Vol. 2023 Oct;48(9):877-883. doi: 10.1177/17531934231179581. Epub 2023 Jun 13. PubMed 37310049 ↗
  • Kriegs-Au G, Petje G, Fojtl E, Ganger R, Zachs I. Ligament reconstruction with or without tendon interposition to treat primary thumb carpometacarpal osteoarthritis. A prospective randomized study. J Bone Joint Surg Am. 2004 Feb;86(2):209-18. doi: 10.2106/00004623-200402000-00001. PubMed 14960663 ↗
  • Guzzini M, Arioli L, Annibaldi A, Pecchia S, Latini F, Ferretti A. Interposition Arthroplasty versus Dual Cup Mobility Prosthesis in Treatment of Trapeziometacarpal Joint Osteoarthritis: A Prospective Randomized Study. Hand (N Y). 2024 Nov;19(8):1260-1268. doi: 10.1177/15589447231185584. Epub 2023 Jul 23. PubMed 37482747 ↗
  • Newton A, Talwalkar S. Arthroplasty in thumb trapeziometacarpal (CMC joint) osteoarthritis: An alternative to excision arthroplasty. J Orthop. 2022 Nov 26;35:134-139. doi: 10.1016/j.jor.2022.11.011. eCollection 2023 Jan. PubMed 36471695 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data that underlie the results reported in this article (text, tables, figures, and appendices) will be made available to researchers who provide a methodologically sound proposal. Data will be available beginning 6 months and ending 5 years after publication. Requests should be directed to Central contact person. To gain access, data requestors will need to sign a data access agreement and provide proof of approval from the Swedish Ethical Review Authority.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Beginning 6 months and ending 5 years after publication

Access criteria: Access will be granted to qualified academic researchers who provide a methodologically sound scientific proposal. The request must be consistent with the informed consent provided by the participants. Access requires a formal Data Sharing Agreement (DSA) and a valid ethical approval from the Swedish Ethical Review Authority (Etikprövningsmyndigheten). The requesting party must also demonstrate that they have the necessary infrastructure to handle sensitive data according to GDPR

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Sep 2026 (actual). Primary completion is estimated for May 2030, 44 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Sep 2026, on Oct 9, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2026
First posted
May 6, 2026
StartActual
Sep 4, 2026was Jul 2026
Primary completionEst.
May 2030
CompletionEst.
Mar 2038
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site removed
Show 1 removed
  • Örebro university hospital · Örebro, Sweden
Oct 9, 2026
Start date
Jul 1, 2026→Sep 4, 2026 (actual)
Oct 9, 2026
Eligibility
1 exclusion criterion edited
What changed in the criteria
Exclusion criteria
  • ChangedBefore Ongoing chronic pain conditionNow Ongoing general chronic pain condition or other pain in the same hand predominant over the thumb base pain.
Oct 9, 2026
Secondary outcomes
10 time frame changed
What changed in the outcomes
  • Time frameKey-pinch grip strengthMeasured at 6 weeks, 12 weeks, and 12 months postoperatively → Measured at 6 weeks, 12 weeks, 12 months, 2 years, 5 years and 10 years postoperatively
  • Time framePinch grip strengthMeasured at 6 weeks, 12 weeks and 12 months postoperatively → Measured at 6 weeks, 12 weeks, 12 months, 2 years, 5 years and 10 years postoperatively
  • Time framePostoperative Pain Intensity on a Numeric Rating Scale (NRS)Measured at 6 weeks, 12 weeks and 12 months postoperatively → Measured at 6 weeks, 12 weeks, 12 months, 2 years, 5 years and 10 years postoperatively
  • Time frameRange of movementMeasured at 6 weeks, 12 weeks and 12 months postoperatively → Measured at 6 weeks, 12 weeks, 12 months, 2 years, 5 years and 10 years postoperatively
  • Time frameMetacarpophalangeal (MCP)-joint hyperextensionMeasured at 6 weeks, 12 weeks and 12 months postoperatively → Measured at 6 weeks, 12 weeks, 12 months, 2 years, 5 years and 10 years postoperatively
  • Time frameComplicationsMeasured at 6 weeks, 12 weeks and 12 months postoperatively → Measured at 6 weeks, 12 weeks, 12 months, 2 years, 5 years and 10 years postoperatively
  • Time frameUse of analgesicsMeasured at 12 months postoperatively → Measured at 6 weeks, 12 weeks, 12 months, 2 years, 5 years and 10 years postoperatively
  • Time frameDuration of sick leaveMeasured at 12 months postoperatively → Measured at 6 weeks, 12 weeks, 12 months, 2 years, 5 years and 10 years postoperatively
  • Time framePatient-reported outcomes EQ-5DMeasured at 6 weeks, 12 weeks and 12 months postoperatively → Measured at 6 weeks, 12 weeks, 12 months, 2 years, 5 years and 10 years postoperatively
  • Time framePatient-reported outcomes PRWHEMeasured at 6 weeks, 12 weeks and 12 months postoperatively → Measured at 6 weeks, 12 weeks, 12 months, 2 years, 5 years and 10 years postoperatively
Oct 9, 2026
Sponsor
Collaborators removed: Örebro County Council
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    1 site removed
    Show 1 removed
    • Örebro university hospital · Örebro, Sweden
    Start date Jul 1, 2026→Sep 4, 2026 (now actual)
    Eligibility 1 exclusion criterion edited
    What changed in the criteria
    Exclusion criteria
    • ChangedBefore Ongoing chronic pain conditionNow Ongoing general chronic pain condition or other pain in the same hand predominant over the thumb base pain.
    Secondary outcomes 10 time frame changed
    What changed in the outcomes
    • Time frameKey-pinch grip strengthMeasured at 6 weeks, 12 weeks, and 12 months postoperatively → Measured at 6 weeks, 12 weeks, 12 months, 2 years, 5 years and 10 years postoperatively
    • Time framePinch grip strengthMeasured at 6 weeks, 12 weeks and 12 months postoperatively → Measured at 6 weeks, 12 weeks, 12 months, 2 years, 5 years and 10 years postoperatively
    • Time framePostoperative Pain Intensity on a Numeric Rating Scale (NRS)Measured at 6 weeks, 12 weeks and 12 months postoperatively → Measured at 6 weeks, 12 weeks, 12 months, 2 years, 5 years and 10 years postoperatively
    • Time frameRange of movementMeasured at 6 weeks, 12 weeks and 12 months postoperatively → Measured at 6 weeks, 12 weeks, 12 months, 2 years, 5 years and 10 years postoperatively
    • Time frameMetacarpophalangeal (MCP)-joint hyperextensionMeasured at 6 weeks, 12 weeks and 12 months postoperatively → Measured at 6 weeks, 12 weeks, 12 months, 2 years, 5 years and 10 years postoperatively
    • Time frameComplicationsMeasured at 6 weeks, 12 weeks and 12 months postoperatively → Measured at 6 weeks, 12 weeks, 12 months, 2 years, 5 years and 10 years postoperatively
    • Time frameUse of analgesicsMeasured at 12 months postoperatively → Measured at 6 weeks, 12 weeks, 12 months, 2 years, 5 years and 10 years postoperatively
    • Time frameDuration of sick leaveMeasured at 12 months postoperatively → Measured at 6 weeks, 12 weeks, 12 months, 2 years, 5 years and 10 years postoperatively
    • Time framePatient-reported outcomes EQ-5DMeasured at 6 weeks, 12 weeks and 12 months postoperatively → Measured at 6 weeks, 12 weeks, 12 months, 2 years, 5 years and 10 years postoperatively
    • Time framePatient-reported outcomes PRWHEMeasured at 6 weeks, 12 weeks and 12 months postoperatively → Measured at 6 weeks, 12 weeks, 12 months, 2 years, 5 years and 10 years postoperatively
    Sponsor Collaborators removed: Örebro County Council
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07569549
Lead sponsor
Uppsala University
Collaborators
Uppsala County Council, Sweden
Responsible party
Sponsor
First posted
May 6, 2026
Start date
Sep 4, 2026
Primary completion
May 2030 (estimated)
Completion
Mar 2038 (estimated)
Last update
Oct 9, 2026

Study contacts

Eva Nordin, Clinical research nurse
Contact
eva.nordin@akademiska.se
+46(0) 186119630
Elias Gardell, MD, attending hand surgeon
Contact
elias.gardell@uu.se
+46 (0) 186171544
Nils Hailer, MD, PhD. Professor
study director · Department of orthopaedics and hand surgery, Akademiska hospital, Uppsala, Sweden
Sara Edsfeldt, MD, PhD, senior attending
principal investigator · Department of orthopaedics and hand surgery, Akademiska hospital, Uppsala, Sweden
Sara Edsfeldt, MD, PhD, senior attending
study chair · Department of orthopaedics and hand surgery, Akademiska hospital, Uppsala, Sweden

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion